Clene to Present at the Canaccord 45th Annual Growth Conference

Rhea-AI Summary

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments, will present at the Canaccord 45th Annual Growth Conference on August 12th, 2025, at 3:30pm ET in Boston, MA.

The company, which focuses on developing treatments for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), will conduct a presentation and host one-on-one investor meetings. A webcast will be available through the company's website and online registration.

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings.

Date: August 12th, 2025
Time of Presentation: 3:30pm ET
Location: Boston, MA
Format: Presentation
1x1 Meetings: Please contact your Canaccord representative

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When and where will Clene (CLNN) present at the Canaccord Growth Conference?

Clene will present at the Canaccord Growth Conference on August 12th, 2025 at 3:30pm ET in Boston, MA.

What diseases does Clene (CLNN) focus on treating?

Clene focuses on treating neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

How can investors access Clene's Canaccord conference presentation?

Investors can access the presentation webcast through the 'Events' section of Clene's website or via online registration.

What type of meetings will Clene (CLNN) host at the Canaccord conference?

Clene will conduct a presentation and host one-on-one investor meetings. Investors interested in 1x1 meetings should contact their Canaccord representative.